Mesoblast Limited (ASX: MSB) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Mesoblast Limited Chart and Price Data
Fundamentals Data provided by Morningstar.
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Mesoblast Limited (ASX: MSB)
Latest News
Share Market News
Why the Mesoblast (ASX:MSB) share price gained today as the ASX 200 fell
Share Gainers
Why Coles, HUB24, Mesoblast, & Temple & Webster shares are pushing higher
⏸️ ASX Shares
These are the 10 most shorted shares on the ASX
Share Fallers
Why CIMIC, Megaport, Mesoblast, & Temple & Webster shares are dropping lower
Share Fallers
What happened to the Mesoblast Limited (ASX:MSB) share price?
Share Market News
ASX 200 Weekly Wrap: Promises of easy money push ASX 200 to post-crash high
Share Market News
These are the 10 most shorted shares on the ASX
Share Fallers
These were the worst performing shares on the ASX 200 last week
Share Market News
Short-sellers are stepping up their attack on these ASX stocks
Share Market News
Zip and Estrella Resources were among the most traded shares on the ASX last week
Share Market News
These are the 10 most shorted shares on the ASX
Share Market News
A2 Milk and Mesoblast were among the most traded shares on the ASX last week
Frequently Asked Questions
-
No, Mesoblast does not pay shareholder dividends at this time.
-
Yes, Mesoblast is listed on the ASX and the US Nasdaq under the ticker code NASDAQ: MESO.
-
Mesoblast Ltd listed on the ASX on 16 December 2004.
MSB ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Mesoblast Limited
Mesoblast Ltd (ASX: MSB) is a clinical-stage biotechnology company. It develops and commercialises allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care.
Its portfolio of Phase 3 product candidates includes its flagship remestemcel-L for the treatment of steroid-refractory acute graft versus host disease (SR-aGVHD) as well as moderate to severe acute respiratory distress syndrome (ARDS). Its other candidates include REVASCOR® for advanced chronic heart failure and MPC-06-ID for chronic low back pain due to degenerative disc disease. These cell therapy candidates are towards the latter stages of their clinical trial pipelines.
Mesoblast has locations in Australia, the United States, and Singapore and is dual-listed on the ASX and the US Nasdaq (NASDAQ: MESO).
